

Publisher: John Wiley & Sons Inc
E-ISSN: 1860-7187|10|12|2004-2013
ISSN: 1860-7179
Source: CHEMMEDCHEM, Vol.10, Iss.12, 2015-12, pp. : 2004-2013
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
AbstractHaving recently identified a so‐far unexplored area adjacent to the known binding site of allosteric mitogen‐activated protein kinase kinase (MEK) inhibitors, we now report an extension of these studies by combining our new side chains with different MEK inhibitor cores in a modular manner. Replacement of the amide headgroup with inverse sulfonamides resulted in the identification of new MEK inhibitors with at least 10‐fold higher cellular potency against K‐Ras‐mutated tumor cells. A selected inhibitor from this new series retained the favorable pharmacokinetic profile of its predecessor in rodent and non‐rodent species and displayed significant in vivo efficacy at once‐daily oral doses of 0.25–1 mg kg−1 in a K‐Ras‐mutated xenograft model. The brain penetration potential of this analogue was significantly attenuated relative to PD325901. In a second series, the central fluorophenyl core was replaced by a pyridine moiety which gave rise to a similar boost in cellular potency. Most notably, analogues from this second series do not show MEK feedback phosphorylation in K‐Ras‐mutated A549 cells. Our results complement recent reports on the structural intricacies of MEK–Raf feedback interactions.
Related content




Modular assembly of elliptical mesogens
By Lavigueur Christine Foster Johan E. Williams Vance E.
Liquid Crystals, Vol. 34, Iss. 7, 2007-07 ,pp. :



